Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 701–800 of 1,007
Korsisaari, N., Ross, J., Wu, X., Kowanetz, M., Pal, N., Hall, L., Eastham‐Anderson, J., Forrest, W. F., van Bruggen, N., Peale, F. V., Jr., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1552 · Cited by 62
“It is now well established that angiogenesis also plays an important role in the pathogenesis of several disorders (3, 4).”
BackgroundSelf-citationTherapeutic options targeting angiogenesis in nonsmall cell lung cancer
Crinò, L., & Metro, G. (2014) · European Respiratory Review · doi:10.1183/09059180.00008913 · Cited by 59
Smith, G. A., Fearnley, G. W., Tomlinson, D. C., Harrison, M. A., & Ponnambalam, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150171 · Cited by 69
Cardiotoxicity of systemic agents used in breast cancer
Ades, F., Zardavas, D., Pinto, A. C., Criscitiello, C., Aftimos, P. G., & de Azambuja, E. (2014) · The Breast · doi:10.1016/j.breast.2014.04.002 · Cited by 70
Notch Regulation of Tumor Angiogenesis
Bridges, E., Oon, C. E., & Harris, A. L. (2011) · Future Oncology · doi:10.2217/fon.11.20 · Cited by 65
“Therefore, it is unsurprising that over the last decade of research, numerous inhib itors of angiogenesis, mainly targeting the VEGF pathway, have emerged and been clinically vali dated for cancer therapy [200,201].”
BackgroundPenack, O., Henke, E., Suh, D. Y., King, C. G., Smith, O. M., Na, I., Holland, A. M., Ghosh, A., Lu, S. X., Jenq, R. R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq172 · Cited by 65
Pace, J. R., DeBerardinis, A. M., Sail, V., Tacheva-Grigorova, S. K., Chan, K. A., Tran, R., Raccuia, D. S., Wechsler-Reya, R. J., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01718 · Cited by 60
Kim, T. H., Jung, Y., & Kim, S. H. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0318 · Cited by 59
“14–16 Although angiogenesis has an important role in wound healing, there is a lack of research on wound dressings and their effect on angiogenesis.”
von Mensdorff‐Pouilly, S. (2017) · Springer eBooks · doi:10.1007/978-3-662-46875-3_6630 · Cited by 60
He, Z., Zhong, Y., Regmi, P., Lv, T., Ma, W., Wang, J.-K., Liu, F., Yang, S., Zhong, Y., Zhou, R., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01979-z · Cited by 59
“Angiogenesis is a crucial physiological process for the growth, invasion, and metastasis of tumors, and abnormal angiogenic activity is associated with chemoresistance [33].”
BackgroundFiorio, A., Avanzato, D., Munaron, L., & Ambudkar, I. S. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00280.2011 · Cited by 62
“Indeed an increasing amount of novel experimental evidence obtained from in vitro and in vivo challenge the classical angiogenesis model forcing us to consider new scenarios to explain the process of tumor neovascularization (10, 20, 33, 62, 66).”
BackgroundYang, M., Zou, J., Zhu, H., Liu, S., Wang, H., Bai, P., & Xiao, X. (2015) · Oncology Reports · doi:10.3892/or.2015.3836 · Cited by 62
Honek, J., Seki, T., Iwamoto, H., Fischer, C., Li, J., Lim, S., Samani, N. J., Zang, J., & Cao, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415825111 · Cited by 60
Pathological angiogenesis facilitates tumor cell dissemination and metastasis
Rouhi, P., Lee, S. L. C., Cao, Z., Hedlund, E., Jensen, L. D., & Cao, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.5.10853 · Cited by 61
Finger, P. T., & Chin, K. J. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.075 · Cited by 59
Eichten, A., Su, J., Adler, A. P., Zhang, L., Ioffe, E., Parveen, A. A., Yancopoulos, G. D., Rudge, J., Lowy, I., Lin, H. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1443 · Cited by 58
“Blockade of the VEGF pathway is effective at inhibiting angiogenesis in many tumors (1-3).”
BackgroundChen, F., Sun, Y., Zheng, S., Qin, Y., McClements, D. J., Hu, J., & Deng, Z. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.03.013 · Cited by 59
Vaidya, G. N., Rana, P., Venkatesh, A., Chatterjee, D. R., Contractor, D., Satpute, D. P., Nagpure, M., Jain, A. K., & Kumar, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112844 · Cited by 61
Bottos, A., Martini, M., Di Nicolantonio, F., Comunanza, V., Maione, F., Minassi, A., Appendino, G., Bussolino, F., & Bardelli, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105026109 · Cited by 60
“Antiangiogenic therapies have been developed to target this course of action, which is primarily driven by soluble growth factors such as VEGF (33, 34).”
BackgroundBayerl, S., Niesner, R. A., Cseresnyés, Z., Radbruch, H., Pohlan, J., Brandenburg, S., Czabanka, M., & Vajkoczy, P. (2016) · Glia · doi:10.1002/glia.22994 · Cited by 63
Mançanares, C. A. F., Souza, V. C. D. O., Oliveira, L. J., Miglino, M. A., Meirelles, F. V., & Ambrósio, C. E. (2019) · Stem Cells International · doi:10.1155/2019/5073745 · Cited by 58
“mobilized in situ or transplanted, have become one of the main targets of therapeutic approaches for revascularization in ischemic diseases and endothelial injury [20].”
BackgroundCox, J. (2009) · Frontiers in Bioscience · doi:10.2741/3255 · Cited by 58
Lee, Y.-M., Lim, J.-H., Yoon, H., Chun, Y., & Park, J. (2010) · Hepatology · doi:10.1002/hep.24010 · Cited by 58
“Therefore, antibodies and peptides that antagonize VEGF or its receptors have been developed as anticancer therapies.(23,24) We found that chaetocin inhibits VEGF production in hepatoma cells and grafts, and that vessels were poorly developed in chaetocin-treated tumors.”
BackgroundFujita, M., Khazenzon, N. M., Ljubimov, A. V., Lee, B., Virtanen, I., Holler, E., Black, K. L., & Ljubimova, J. Y. (2006) · Angiogenesis · doi:10.1007/s10456-006-9046-9 · Cited by 58
“metronomic chemotherapy may further enhance the efficacy of glioma treatment [36, 37].”
BackgroundPlacental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
Bagley, R. G., Ren, Y., Weber, W. D., Yao, M., Kurtzberg, L. S., Pinckney, J., Bangari, D. S., Nguyen, C., Brondyk, W. H., Kaplan, J. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2687 · Cited by 58
Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease
Smith, G. A., Fearnley, G. W., Harrison, M. A., Tomlinson, D. C., Wheatcroft, S. B., & Ponnambalam, S. (2015) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-015-9838-4 · Cited by 64
“Altered response to VEGF-A can cause pathological angiogenesis leading to chronic inflammatory diseases, ischemic heart disease, cancer, and retinopathy (Carmeliet 2005; Coultas et al 2005; Ferrara and Kerbel 2005).”
BackgroundJeong, S. K., Kim, J., Lee, C. G., Park, Y.-S., Kim, S., Yoon, S. O., Han, D. H., Lee, K. Y., Jeong, M. H., & Jo, W. S. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.11.010 · Cited by 60
Somatic mutations in histiocytic sarcoma identified by next generation sequencing
Liu, Q., Tomaszewicz, K., Hutchinson, L., Hornick, J. L., Woda, B. A., & Yu, H. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1965-2 · Cited by 64
Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer
Matsuda, N., Lim, B., Wang, X., & Ueno, N. T. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1299707 · Cited by 68
Zhao, B., Liu, L., Mao, J., Zhang, Z., Wang, Q., & Li, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0348-9 · Cited by 62
Developing Antiangiogenic Peptide Drugs for Angiogenesis-Related Diseases
Sulochana, K. N., & Ge, R. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781039715 · Cited by 60
ANGIOGENESIS AND GLIOMAS: CURRENT ISSUES AND DEVELOPMENT OF SURROGATE MARKERS
Jouanneau, E. (2008) · Neurosurgery · doi:10.1227/01.neu.0000311060.65002.4e · Cited by 65
“1 from tumors can recruit these EPCs by acting upon their maturation (49, 67, 77).”
BackgroundSex-steroid regulation of vascular endothelial growth factor in breast cancer
Hyder, S. M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00931 · Cited by 63
“…that strong scientific evidence has been acquired proving that breast cancer is an angiogenicdependent disease, which is potentially treatable by antiangiogenic therapy (Longo et al. 2002, Atqur-Rehman& Toi 2003,Morabito et al.2004,Moses et al.2004, Ferrara & Kerbel 2005, Schneider & Miller 2005).”
BackgroundAn allosteric peptide inhibitor of HIF-1α regulates hypoxia-induced retinal neovascularization
Usui‐Ouchi, A., Aguilar, E., Murinello, S., Prins, M., Gantner, M. L., Wright, P. E., Berlow, R. B., & Friedlander, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017234117 · Cited by 63
Loessner, D., Holzapfel, B. M., & Clements, J. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.001 · Cited by 57
Muraki, C., Ohga, N., Hida, Y., Nishihara, H., Kato, Y., Tsuchiya, K., Matsuda, K., Totsuka, Y., Shindoh, M., & Hida, K. (2012) · International Journal of Cancer · doi:10.1002/ijc.25976 · Cited by 57
“In the tumor microenvironment, angiogenesis is necessary for tumor progression and metastasis.(2) Control of tumor angiogenesis is therefore a very important preventive strategy against invasive cancers.”
BackgroundGiordano, G., Febbraro, A., Venditti, M., Campidoglio, S., Olivieri, N., Raieta, K., Parcesepe, P., Imbriani, G. C., Remo, A., & Pancione, M. (2014) · Gastroenterology Research and Practice · doi:10.1155/2014/526178 · Cited by 64
“In the last decade, different antiangiogenic strategies have been investigated in preclinical and clinical studies, showing how angiogenesis can be targeted by several approaches [64, 65].”
BackgroundOyama, O., Sugimoto, N., Qi, X., Takuwa, N., Mizugishi, K., Koizumi, J., & Takuwa, Y. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn002 · Cited by 57
Pharmacologic Therapy for Periocular Infantile Hemangiomas: A Review of the Literature
Nguyen, J., & Fay, A. M. (2009) · Seminars in Ophthalmology · doi:10.1080/08820530902805602 · Cited by 57
Huang, M., Qiu, Q., Xiao, Y., Zeng, S., Zhan, M., Shi, M., Zou, Y., Ye, Y., Liang, L., Yang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep23770 · Cited by 64
The Neurovascular Properties of Dental Stem Cells and Their Importance in Dental Tissue Engineering
Ratajczak, J., Bronckaers, A., Dillen, Y., Gervois, P., Vangansewinkel, T., Driesen, R. B., Wolfs, E., Lambrichts, I., & Hilkens, P. (2016) · Stem Cells International · doi:10.1155/2016/9762871 · Cited by 63
“However, the limited success of growth factor-based revascularization urged the need to promote angiogenesis with a more regenerative approach by means of stem cell-based therapies [46, 47].”
Recent Development of Metal Nanoparticles for Angiogenesis Study and Their Therapeutic Applications
Barui, A. K., Nethi, S. K., Haque, S., Basuthakur, P., & Patra, C. R. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00587 · Cited by 61
A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk
Gentles, A. J., Hui, A. B., Feng, W., Azizi, A., Nair, R. V., Bouchard, G., Knowles, D. A., Yu, A., Jeong, Y., Bejnood, A., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02019-x · Cited by 63
Functional VEGF and VEGF receptors are expressed in human medulloblastomas
Slongo, M. L., Molena, B., Brunati, A. M., Frasson, M., Gardiman, M. P., Carli, M., Perilongo, G., Rosolen, A., & Onisto, M. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-032 · Cited by 57
Ding, C., Li, L., Yang, T., Fan, X., & Wu, G. (2016) · BMC Cancer · doi:10.1186/s12885-016-2834-8 · Cited by 56
Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer
Komatsu, H., Oishi, T., Itamochi, H., Shimada, M., Sato, S., Chikumi, J., Sato, S., Nonaka, M., Sawada, M., Wakahara, M., et al. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001027 · Cited by 57
Fu, R., Li, Y., Jiang, N., Ren, B., Zang, C.-Z., Liu, L., Lv, W., Li, H., Weiss, S. J., Li, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131507 · Cited by 64
Cisplatin-Induced Reproductive Toxicity and Oxidative Stress: Ameliorative Effect of Kinetin
Abdellatif, R., Fathy, M., Anwar, H. A., Naseem, M., Dandekar, T., & Othman, E. M. (2022) · Antioxidants · doi:10.3390/antiox11050863 · Cited by 67
“Although the use of chemotherapy significantly increases the cure rate of many malignancies and improves patients’ survival rates, the classical chemotherapeutic drugs are cytotoxic and do not distinguish between cancer and normal cells [3], and as a consequence, the patients develop serious side effects that are cons…”
BackgroundVessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R. J. H., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 59
The role of targeted therapy in ovarian cancer
Banerjee, S. N., & Kaye, S. B. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70155-1 · Cited by 64
Moyle, C. W. A., Cerezo, A. B., Winterbone, M. S., Hollands, W. J., Alexeev, Y., Needs, P. W., & Kroon, P. A. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400478 · Cited by 56
“VEGF receptor-2 (VEGFR-2) is the major mediator of the mitogenic, angiogenic and permeability enhancing effects of VEGF [6, 7].”
BackgroundBen, Q., Zheng, J., Fei, J., An, W., Li, P., Li, Z., & Yuan, Y. (2014) · Pancreas · doi:10.1097/mpa.0000000000000117 · Cited by 56
Small, W. C., Mulcahy, M. F., RADEMAKER, A. W., Bentrem, D. J., Benson, A. B., Weitner, B. B., & Talamonti, M. S. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.02.030 · Cited by 57
Loupakis, F., Bria, E., Vaccaro, V., Cuppone, F., Milella, M., Carlini, P., Cremolini, C., Salvatore, L., Falcone, A., Muti, P. C., et al. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-58 · Cited by 65
“Introduction The intuition of the relevant role of newly and aberrantly formed blood vessels in driving tumor progression has represented the rational basis to assess the implication of antiangiogenesis as a therapeutic strategy [1].”
Ginger: A Novel Strategy to Battle Cancer through Modulating Cell Signalling Pathways: A Review
Almatroudi, A., Alsahli, M. A., Alrumaihi, F., Allemailem, K. S., & Rahmani, A. H. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666190119142331 · Cited by 57
The role of apoptosis in radiation oncology
Meyn, R. E., Milas, L., & Ang, K. K. (2009) · International Journal of Radiation Biology · doi:10.1080/09553000802662595 · Cited by 56
IL-3 is a novel target to interfere with tumor vasculature
Dentelli, P., Rosso, A., Olgasi, C., Camussi, G., & Brizzi, M. F. (2011) · Oncogene · doi:10.1038/onc.2011.204 · Cited by 57
Structure–Activity Relationships of C-17 Cyano-Substituted Estratrienes as Anticancer Agents
Leese, M. P., Jourdan, F. L., Gaukroger, K., Mahon, M. F., Newman, S. P., Foster, P., Stengel, C., Regis-Lydi, S., Ferrandis, E., Fiore, A. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701319c · Cited by 60
Kim, J. H., Lee, J. S., Kang, K. W., Lee, H., Han, S., Kim, T., Lee, Y., Jeong, J. M., & Lee, D. S. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.1061 · Cited by 55
Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth
Segarra, M., Williams, C. K., Sierra, M. D. L. L., Bernardo, M., McCormick, P. J., Maric, D., Regino, C. A. S., Choyke, P. L., & Tosato, G. (2008) · Blood · doi:10.1182/blood-2007-11-126045 · Cited by 61
Celecoxib Nanoparticles for Therapeutic Angiogenesis
Margulis, K., Neofytou, E. A., Beygui, R. E., & Zare, R. N. (2015) · ACS Nano · doi:10.1021/acsnano.5b04137 · Cited by 55
Zhou, Y., Deng, R., Zhen, M., Li, J., Guan, M., Jia, W., Li, X., Zhang, Y., Yu, T., Zou, T., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.025 · Cited by 55
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 60
Clinical and prognostic value of the C‐Met/HGF signaling pathway in cervical cancer
Boromand, N., Hasanzadeh, M., Shahidsales, S., Farazestanian, M., Gharib, M., Fiuji, H., Behboodi, N., Ghobadi, N., Hassanian, S. M., Ferns, G. A., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26232 · Cited by 55
“Subsequently, elevated HIF-1α promotes the genes that have been implicated in cell survival, metastasis, metabolism as well as angiogenesis and invasion (Ferrara & Kerbel, 2005; Semenza, 2003).”
BackgroundChemotherapy Treatment and Strategy Schemes: A Review
Alam, A. (2018) · Open Access Journal of Toxicology · doi:10.19080/oajt.2018.02.555600 · Cited by 55
Sennino, B., Kuhnert, F., Tabruyn, S. P., Mancuso, M. R., Hu‐Lowe, D. D., Kuo, C. J., & McDonald, D. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3779 · Cited by 64
Kluza, E., Yeo, S. Y., Schmid, S., van der Schaft, D. W. J., Boekhoven, R. W., Schiffelers, R. M., Storm, G., Strijkers, G. J., & Nicolay, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.031 · Cited by 54
Liang, N. N., Li, Y.-L., & Chung, H. Y. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4004 · Cited by 54
“Research on tumor angiogenesis progressed slowly until the discovery of the key molecular initiators of angiogenesis, i.e., the vascular endothelial growth factor (VEGF), and its endothelial cell specific tyrosine kinase receptor VEGFR (3).”
LW-215, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo
Zhao, K., Yuan, Y., Lin, B., Miao, Z., Li, Z., Guo, Q., & Lu, N. (2017) · Gene · doi:10.1016/j.gene.2017.11.065 · Cited by 58
Xie, C., Mondal, D. K., Ulas, M., Neill, T., & Iozzo, R. V. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00016.2022 · Cited by 62
Advances in Growth Factor Delivery for Therapeutic Angiogenesis
Said, S. S., Pickering, J. G., & Mequanint, K. (2012) · Journal of Vascular Research · doi:10.1159/000345108 · Cited by 55
Triple-negative breast cancer: investigating potential molecular therapeutic target
Papa, A., Caruso, D., Tomao, F., Rossi, L., Zaccarelli, E., & Tomao, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.970176 · Cited by 58
HSPA12B Is Predominantly Expressed in Endothelial Cells and Required for Angiogenesis
Steagall, R. J., Rusiñol, A. E., Truong, Q. A., & Han, Z. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000235720.61091.c7 · Cited by 55
Bioinorganic aspects of angiogenesis
D’Andrea, L. D., Romanelli, A., Stasi, R. D., & Pedone, C. (2010) · Dalton Transactions · doi:10.1039/c002439b · Cited by 56
Cascio, S., Ferla, R., D'Andrea, A., Gerbino, A., Bazan, V., Surmacz, E., & Russo, A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21843 · Cited by 53
“New blood vessels formation depends on the balance between positive and negative regulators and is induced when factors that promote angiogenesis are upregulated or those that inhibit angiogenesis are down-regulated (Ferrara and Kerbel, 2005).”
BackgroundBreast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype
Allouch, S., Gupta, I., Malik, S., Farsi, H. F. A., Vranić, S., & Moustafa, A. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580345 · Cited by 59
Drug repurposing—an emerging strategy in cancer therapeutics
Turabi, K. S., Deshmukh, A. J., Paul, S., Swami, D., Siddiqui, S., Kumar, U., Naikar, S., Devarajan, S., Basu, S., Paul, M. K., et al. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02263-x · Cited by 61
“Various studies have found that anti-angiogenesis activity or inhibition of angiogenesis can be utilized as a methodology to effectively treat cancer (Ferrara and Kerbel 2005).”
MethodThe application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Tu, J., Liang, H., Li, C., Huang, Y., Wang, Z., Chen, X., & Yuan, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198972 · Cited by 56
“On the one hand, the new tumor vasculature is believed to provide nutrients and oxygen to the proliferation and distant metastasis of tumor cells, which led to the proposal of antiangiogenic therapy (16); on the other hand, it was found that the excessive elimination of tumor vasculature after antiangiogenic therapy m…”
BackgroundDeficient angiogenesis in redox-dead Cys17Ser PKARIα knock-in mice
Burgoyne, J. R., Rudyk, O., Cho, H.-J., Prysyazhna, O. D., Hathaway, N., Weeks, A. J., Evans, R., Ng, T., Schröder, K., Brandes, R. P., et al. (2015) · Nature Communications · doi:10.1038/ncomms8920 · Cited by 62
Strieth, S., Nußbaum, C., Eichhorn, M., Fuhrmann, M., Teifel, M., Michaelis, U., Berghaus, A., & Dellian, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.23088 · Cited by 57
“Currently, extensive experimental work is performed to successfully explore the potential of antivascular strategies in cancer therapy.(1) Numerous antiangiogenic substances are currently under evaluation in clinical studies.”
BackgroundResultIntegrin-targeted paclitaxel nanoliposomes for tumor therapy
Meng, S., Su, B., Li, W., Ding, Y., Tang, L., Zhou, W., Song, Y., & Caicun, Z. (2010) · Medical Oncology · doi:10.1007/s12032-010-9621-1 · Cited by 53
“Since angiogenesis is crucially required for solid tumor growth and metastasis [ 7 ], tumor vasculature has been considered to be an ideal target for cancer treatment.”
BackgroundAntiangiogenesis to treat cancer and intraocular neovascular disorders
Shojaei, F., & Ferrara, N. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700526 · Cited by 54
“5 Clinical development of anti-VEGF agents The existence of numerous angiogenic factors, including EGF, TGF- α TGF- β , acidic and basic FGF (reviewed by Ferrara and Kerbe”
BackgroundSelf-citationAge-related macular degeneration: current treatments
Hubschman, J., Reddy, S., & Schwartz, S. D. (2009) · Clinical ophthalmology · doi:10.2147/opth.s2094 · Cited by 60
“Multiple studies have suggested that vascular endothelial growth factor (VEGF) increases vascular permeability and is involved in the pathogenesis of neovascularization in human eye disease.(40) Current approaches to inhibit VEGF involve binding it to a molecule that prevents receptor 0-ligand interaction, thus incapa…”
BackgroundThe neurotransmitter dopamine modulates vascular permeability in the endothelium
Bhattacharya, R., Sinha, S., Yang, S.-P., Patra, C. R., Dutta, S. K., Wang, E., & Mukhopadhyay, D. (2008) · Journal of Molecular Signaling · doi:10.1186/1750-2187-3-14 · Cited by 54
“In fact, there is evidence that inhibition of VPF/VEGF can lead to decreased formation of pleural effusions [3,8] and that antibodies directed against VPF/VEGF or VEGFR-2 can lead to a decrease in tumor vessel permeability and ascites formation [1,3,8-10].”
BackgroundYu, J., Zhang, Y., Leung, L.-H., Liu, L., Yang, F., & Yao, X. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0340-8 · Cited by 54
Mawalla, B. C., Yuan, X., Luo, X., & Chalya, P. L. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3137-8 · Cited by 53
Kang, D., Pang, X., Lian, W., Xu, L., Wang, J., Jia, H., Zhang, B., Liu, A., & Du, G. (2018) · RSC Advances · doi:10.1039/c7ra12259d · Cited by 53
Chellappan, D. K., Leng, K. H., Jia, L. J., Aziz, N. A. B. A., Hoong, W. C., Qian, Y. C., Ling, F. Y., Wei, G. S., Ying, T., Chellian, J., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.061 · Cited by 57
Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis
Mukai, M., Komori, K., & Oka, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17027 · Cited by 56
TIMP-2 disrupts FGF-2-induced downstream signaling pathways
Seo, D. W., Kim, S. H., Eom, S.-H., Yoon, H.-J., Cho, Y., Kim, P.-H., Kim, Y. K., Han, J., Diaz, T., Wei, B., et al. (2008) · Microvascular Research · doi:10.1016/j.mvr.2008.07.003 · Cited by 58
“…and organ repair, and also contributes to various pathological processes including primary tumor growth, and initial progression from a pre-malignant tumor into an invasive cancer, as well as a variety of chronic inflammatory diseases (Carmeliet, 2005; Ferrara and Kerbel, 2005; Folkman, 2006).”
BackgroundVascular Endothelial Growth Factor Pharmacogenetics: a New Perspective for Anti-Angiogenic Therapy
Pasqualetti, G., Danesi, R., Tacca, M. D., & Bocci, G. (2006) · Pharmacogenomics · doi:10.2217/14622416.8.1.49 · Cited by 64
“Endothelium 13(2), 63–69 (2006). 10.”
BackgroundInfluentialPalmowski, M., Peschke, P., Huppert, J., Hauff, P., Reinhardt, M., Mäurer, M., Karger, C. P., Scholz, M., Semmler, W., Huber, P. E., et al. (2009) · Neoplasia · doi:10.1593/neo.09540 · Cited by 52
“The recent development of novel antiangiogenic drugs holds great promise for cancer treatment [ 1 ].”
BackgroundNovel Quinazoline-Based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity
Garrison, J. B., Shaw, Y., Chen, C., & Kyprianou, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1662 · Cited by 52
“monoclonal antibodies (bevacizumab) and inhibitors of endothelial cell receptor–associated tyrosine kinase activity (9).”
BackgroundDong, F., Tian, H., Yan, S., Li, L., Dong, X., Wang, F., Li, J., LI, C., Cao, Z., Liu, X., et al. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2140 · Cited by 52
“Therefore, disrupting angiogenesis serves as an important strategy for cancer therapy (26).”
BackgroundYu, Q., Liu, Y., Cao, C., Le, F., Qin, X., Sun, D., & Liu, J. (2014) · Nanoscale · doi:10.1039/c4nr02423k · Cited by 52
Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation
Mu, X., Shi, W. Q., Sun, L., Han, L., Jiang, Z., & Zhang, L. (2012) · Molecules · doi:10.3390/molecules17066854 · Cited by 53
“VEGF-A and VEGFR2 play crucial roles in vessel sprouting and new vessel initiation through the induction of the proliferation, migration, and survival of endothelial cells [20].”
BackgroundMicroRNA‐493 regulates angiogenesis in a rat model of ischemic stroke by targeting MIF
Li, Q., He, Q., Baral, S., Mao, L., Li, Y., Jin, H., Chen, S., An, T., Xia, Y., & Hu, B. (2016) · FEBS Journal · doi:10.1111/febs.13697 · Cited by 52
miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma
Vosgha, H., Ariana, A., Smith, R. A., & Lam, A. K.-Y. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0497 · Cited by 56
Miwa, Y., Hoshino, Y., Shoda, C., Jiang, X., Tsubota, K., & Kurihara, T. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.008 · Cited by 55
Masłowska, K., Halik, P. K., Tymecka, D., Misicka, A., & Gniazdowska, E. (2021) · Cancers · doi:10.3390/cancers13051072 · Cited by 57
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.